Designation of Decitabine (DACOGEN) as an Orphan Drug - Janssen - Cilag Pty Ltd

Overview

The Designation of Decitabine (Dacogen) as an Orphan Drug (Gazette, 2012) was enacted to address the treatment needs of a specific, underserved patient group, namely adult patients aged 65 years and older who are diagnosed with de novo or secondary acute myeloid leukaemia (AML). This legislative action was taken under the Therapeutic Goods Regulations 1990, specifically under subregulation 16J(2), by Dr. Anthony Gill, the Delegate of the Secretary. The primary policy objective was to ensure that patients with rare and serious conditions, such as AML, have access to necessary treatments that may otherwise not be developed or available due to the small size of the affected population. The designation of decitabine (Dacogen) as an orphan drug aims to encourage research, development and availability of therapeutic options for these conditions.

Scope and Application

The Designation of decitabine (DACOGEN) as an Orphan Drug Act, as indicated by the Therapeutic Goods Regulations 1990, applies specifically to the drug decitabine marketed under the name DACOGEN, intended for the treatment of adult patients aged 65 years and over with newly diagnosed de novo or secondary acute myeloid leukaemia (AML). The act designates this specific therapeutic application as an orphan drug, highlighting the rarity of the condition it targets and the need for targeted development and availability of the treatment. The legislation pertains to the sponsor of the drug, in this case, Janssen-Cilag Pty Ltd, and the drug itself, which is administered through an injection form. This designation is confined to the Commonwealth level, governed under the Therapeutic Goods Regulations 1990, and does not extend to other drugs or conditions outside the specified parameters. The act does not provide for exclusions, exemptions, or thresholds in the given text, and any further details regarding the application or restrictions would need to be referred to in the subordinate instruments of the Therapeutic Goods Regulations 1990.

Key Provisions

The primary operative sections of this legislation involve the designation of decitabine (DACOGEN) as an orphan drug, as detailed in section 16J of the Therapeutic Goods Regulations 1990. This designation, executed by Dr. Anthony Gill, the Delegate of the Secretary, specifies that decitabine (DACOGEN) is recognised for treating adult patients aged 65 years or older who have newly diagnosed de novo or secondary acute myeloid leukaemia (AML). This decision was made on 16 October 2012, and it identifies the drug's form, which is an injection, for this particular use. The sponsor of decitabine (DACOGEN) is Janssen-Cilag Pty Ltd. The legislation imposes several obligations on the parties and entities it governs. Firstly, it designates decitabine (DACOGEN) as an orphan drug, which typically includes benefits such as streamlined regulatory processes, potential tax incentives, and market exclusivity. This designation is critical for the sponsor, Janssen-Cilag Pty Ltd, in facilitating the development and marketing of the drug for the specified indication. Additionally, it ensures that the drug meets the necessary regulatory standards to be used for treating the specified group of patients. Breaches of the conditions set out in this legislation may lead to various consequences. Although the specific offences, penalties, or civil/criminal consequences are not detailed in the provided text, it is common under Australian law for non-compliance with therapeutic goods regulations to result in penalties. These may include fines, enforcement actions, or even criminal charges in cases of serious non-compliance. The exact penalties would depend on the nature and severity of the breach, as well as the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990.